Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. covers events occurring between June 29, 2018 and July 10, 2018. The report addresses corporate governance issues, specifically regarding the composition of the Board of Directors and the Audit Committee, and the company's compliance status with the New York Stock Exchange (NYSE).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on governance and listing compliance rather than financial performance.
Material Changes and Governance Events
- Audit Committee Resignation and Rescission: On June 29, 2018, Dr. Mukund Kulkarni resigned from the Audit Committee, causing the company to fall below the NYSE requirement of three members. On July 10, 2018, Dr. Kulkarni rescinded his resignation, and the company accepted it, restoring compliance.
- NYSE Delisting Notice: On July 3, 2018, the company received a notice from the NYSE indicating non-compliance with Section 803(B)(2)(a) of the Company Guide due to the temporary reduction in Audit Committee members.
- Director Departure: On July 10, 2018, Dr. Milton Boniuk resigned as a Director and as a member of the Audit, Compensation, and Nominating Committees.
Outlook, Risks, and Contingencies
Compliance Timeline: The NYSE granted the company a grace period to regain compliance with audit committee composition requirements. The deadline is the earlier of the next annual shareholders' meeting or one year from the event (June 29, 2018). If the annual meeting occurs within 180 days of the event, the deadline is 180 days from the event.
Current Status: As of July 10, 2018, the immediate risk of delisting due to the Audit Committee composition was mitigated by Dr. Kulkarni's return to the committee. However, the resignation of Dr. Boniuk reduces the total number of directors and committee members, which may require further board adjustments to maintain full compliance.
Investor Verification Checklist
- Verify the current total number of directors and independent directors on the Board of Directors following Dr. Boniuk's resignation.
- Confirm the date of the next annual shareholders' meeting to determine the exact deadline for maintaining audit committee compliance.
- Review the attached resignation letter (Exhibit 17.1) for Dr. Milton Boniuk to understand the specific reasons for his departure.
- Monitor subsequent filings to ensure the company has not received further notices regarding board composition or other listing standards.